Clarivate announces it is selling its Life Sciences and Healthcare segment for $600 million. The company says the transaction refines its business focus around AI-driven “transformative intelligence,” centered on its Academia & Government and Intellectual Property segments. Clarivate also states the deal is intended to improve its financial profile, including strengthening the revenue mix, expanding Adjusted EBITDA margin, and lowering capital intensity.
According to Seeking Alpha, Clarivate shares rise sharply—about 16%—following the announcement of the sale. The PR Newswire releases describe the intended strategic and financial effects of the transaction, and indicate that proceeds will be used as part of the company’s broader capital and investment planning (details are not fully included in the provided excerpts).
Overall, the coverage aligns on the key terms of the divestiture—segment sold and purchase price—while presenting the company’s stated rationale as focusing resources on AI-related offerings in its remaining core segments.
